Masonry Blog

Duis eu mauris eget enim pellentesque dignissim vel vel nibh. Proin ut arcu commodo, hendrerit turpis dignissim, fringilla est. Maecenas vitae viverra erat. Duis erat quam.

 Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021 under ticker symbol “AADI”Concurrent $155 … Read More

shadow

FDA grants Priority Review and sets PDUFA target action date of November 26, 2021LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) … Read More

shadow

LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision … Read More

shadow

Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARRO
Tumor-agnostic … Read More

shadow

LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) — Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for … Read More

shadow

Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway … Read More

shadow

EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China
Aadi will receive an upfront payment, regulatory and … Read More

shadow

Rolling submission of U.S. FDA New Drug Application initiated
Long-term follow-up data released at ASCO 2020 for AMPECT … Read More

shadow

Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa

 

Highlights:

Read More

shadow